Resverlogix 주식 가격. RVX - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

0.045

매수가

0.045

매도가

0.045

거래량

0.00 일간 변동폭 0.00

0.04 52주 범위 0.095

market_cap

12.257M

전일 종가

0.045

개장가

최근 거래 시간

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

55,482

발행 주식

272,371,000

배당수익률

주가수익률

-0.65

주당순이익(EPS)

-0.06

매출

57k

순이익

-16.74M

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.resverlogix.com

본부

Calgary, Alberta, Can

설립됨

Resverlogix Corp is listed in the Biological Pds,ex Diagnstics sector of the 토론토 증권거래소 with ticker RVX. The last closing price for Resverlogix was $0.05. Over the last year, Resverlogix shares have traded in a share price range of $ 0.04 to $ 0.095.

Resverlogix currently has 272,371,000 shares in issue. The market capitalisation of Resverlogix is $12.26 million. Resverlogix has a price to earnings ratio (PE ratio) of -0.65.

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0.045	0.045	0.04	32321	0.04416584	CS
4	-0.005	-10	0.05	0.055	0.04	55031	0.04778976	CS
12	-0.01	-18.1818181818	0.055	0.06	0.04	55482	0.05319857	CS
26	-0.045	-50	0.09	0.09	0.04	61792	0.05655433	CS
52	-0.01	-18.1818181818	0.055	0.095	0.04	59047	0.0640302	CS
156	-0.555	-92.5	0.6	0.62	0.04	67036	0.137559	CS
260	-1.235	-96.484375	1.28	1.52	0.04	63951	0.39195659	CS

RVX - Frequently Asked Questions (FAQ)

What is the current Resverlogix share price?

The current share price of Resverlogix is $ 0.045

How many Resverlogix shares are in issue?

Resverlogix has 272,371,000 shares in issue

What is the market cap of Resverlogix?

The market capitalisation of Resverlogix is CAD 12.26M

What is the 1 year trading range for Resverlogix share price?

Resverlogix has traded in the range of $ 0.04 to $ 0.095 during the past year

What is the PE ratio of Resverlogix?

The price to earnings ratio of Resverlogix is -0.65

What is the cash to sales ratio of Resverlogix?

The cash to sales ratio of Resverlogix is 200

What is the reporting currency for Resverlogix?

Resverlogix reports financial results in USD

What is the latest annual turnover for Resverlogix?

The latest annual turnover of Resverlogix is USD 57k

What is the latest annual profit for Resverlogix?

The latest annual profit of Resverlogix is USD -16.74M

What is the registered address of Resverlogix?

The registered address for Resverlogix is 4820 RICHARD ROAD S.W, SUITE 300, CALGARY, ALBERTA, T3E 6L1

What is the Resverlogix website address?

The website address for Resverlogix is www.resverlogix.com

Which industry sector does Resverlogix operate in?

Resverlogix operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
134AUPraise Inc	0.00 (0.00%)	0
1332Nissui Corporation	0.00 (0.00%)	0
132AIN Holdings Co Ltd	0.00 (0.00%)	0
131ACCN Group Corp	0.00 (0.00%)	0
130AVeritas In Silico Inc	0.00 (0.00%)	0
134AUPraise Inc	0.00 (0.00%)	0
1332Nissui Corporation	0.00 (0.00%)	0
132AIN Holdings Co Ltd	0.00 (0.00%)	0
131ACCN Group Corp	0.00 (0.00%)	0
130AVeritas In Silico Inc	0.00 (0.00%)	0
134AUPraise Inc	0.00 (0.00%)	0
1332Nissui Corporation	0.00 (0.00%)	0
132AIN Holdings Co Ltd	0.00 (0.00%)	0
131ACCN Group Corp	0.00 (0.00%)	0
130AVeritas In Silico Inc	0.00 (0.00%)	0

alvaroc2 8 년 전

TA breaking 2,50 try 3 $.

👍️0

alvaroc2 8 년 전

No analist cover at the moment, when news came.....

👍️0

alvaroc2 8 년 전

Good evening clase 2,41 near high 2,47,good news and many conferences in march and april.

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Resverlogix Corp (RVX)

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

Resverlogix Corp 정보

RVX 최신 뉴스

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

RVX - Frequently Asked Questions (FAQ)

이동자

RVX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Resverlogix Corp (RVX) 시세

Resverlogix Corp (RVX)

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

Resverlogix Corp 정보

RVX 최신 뉴스

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

RVX - Frequently Asked Questions (FAQ)

이동자

RVX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거